Investor Presentation Q1 2022
13
Investor presentation
First three months of 2022
ONWARDS 2 completed as the first of six trials in the phase 3
programme for once-weekly insulin icodec
The ONWARDS 2 phase 3a trial has been completed
Insulin icodec ± non-insulin anti-diabetic drugs
R
1:1
Insulin degludec ± non-insulin anti-diabetic drugs
Objective
To confirm the efficacy (non-inferiority on HbA₁) and safety of
once weekly insulin icodec in subjects with type 2 diabetes
treated with basal only insulin
Primary endpoint
Change in HbA₁ from baseline to week 26
26 weeks
Inclusion criteria
•
T2D treated with basal insulin ± OADs* + GLP-1 s.c.
8
Included 526 people with type 2 diabetes
•
Age ≥18 years
HbA1c 7-10%
•
BMI ≤ 40 kg/m2
*Pre-trial all OADs including oral GLP-1s are allowed but SU and glinides are to be discontinued at randomisation
T2D: Type 2 diabetes; OAD: Oral anti Diabetics; s.c.: subcutaneous; BMI: Body-mass index, SU: Sulfonylurea
Novo NordiskⓇView entire presentation